Aller au contenu principal
Accès ouvert déclaré 2026 article

Letermovir for cytomegalovirus prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation: a single-center experience

0Citations signalées — pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

PURPOSE: Letermovir prophylaxis results in a significantly lower risk of clinically significant cytomegalovirus (CMV) infection in adult hematopoietic stem cell transplant recipients. However, studies supporting its efficacy in pediatric patients are limited. METHODS: We retrospectively reviewed the outcomes of ten patients who underwent allogeneic hematopoietic stem cell transplantation and received letermovir prophylaxis between November 2021 and October 2024 at our institution. RESULTS: Among the ten patients, six donors were CMV-seropositive, whereas nine recipients were CMV-seropositive. Six patients (60%) underwent transplantation from mismatched unrelated donors, and two (20%) from haploidentical donors. Five patients (50%) developed acute graft-versus-host disease (GvHD) > grade 2. Ten patients received letermovir prophylaxis for a median of 101.5 days (range, 26-279). The median daily letermovir dose was 4.6 mg/kg (range, 3.5-11.1 mg/kg), with concomitant use of cyclosporin in nine patients. Eight patients (80%) received letermovir as primary prophylaxis, and two (20%) received it as secondary prophylaxis. None of the patients treated with letermovir as primary prophylaxis had CMV reactivation even after discontinuation (median follow-up, 154 days after transplantation, range 37-850). Both patients who received letermovir as secondary prophylaxis showed CMV reactivation. None of the patients developed CMV infection. No significant adverse effects resulting from the letermovir treatment were observed. CONCLUSION: Our data support the feasibility of letermovir prophylaxis in pediatric patients. The optimal dose of letermovir in pediatric patients has not been established. Letermovir, used as secondary prophylaxis in pediatric patients, was well tolerated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Letermovir for cytomegalovirus prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation: a single-center experience
Date Crossref
02/04/2026
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Cytomegalovirus and herpesvirus researchImmunodeficiency and Autoimmune DisordersViral-associated cancers and disorders

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.